Cargando…
ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Autores principales: | Yoon, Shinkyo, Kim, Miso, Hong, Yong Sang, Kim, Han Sang, Kim, Seung Tae, Kim, Jihun, Yun, Hongseok, Yoo, Changhoon, Ahn, Hee Kyung, Kim, Hyo Song, Lee, In Hee, Kim, In-Ho, Park, Inkeun, Jeong, Jae Ho, Cheon, Jaekyung, Kim, Jin Won, Yun, Jina, Lim, Sun Min, Cha, Yongjun, Jang, Se Jin, Zang, Dae Young, Kim, Tae Won, Kang, Jin Hyoung, Kim, Jee Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372582/ https://www.ncbi.nlm.nih.gov/pubmed/37114287 http://dx.doi.org/10.4143/crt.2021.1115.E |
Ejemplares similares
-
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
por: Yoon, Shinkyo, et al.
Publicado: (2022) -
Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)
por: Byeon, Seonggyu, et al.
Publicado: (2020) -
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022) -
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020) -
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06
por: Sohn, Byeong Seok, et al.
Publicado: (2023)